0
0
In response to escalating concerns over the misuse of critical anti-tuberculosis (TB) medications and the growing threat of drug-resistant TB, the Indian government is poised to implement stringent restrictions on the sale of new anti-TB drugs in the private healthcare sector. The proposed measures would limit access to drugs such as Bedaquiline, Delamanid, Pretomanid, and Rifapentine exclusively to government channels under the National TB Elimination Programme (NTEP), effectively barring their sale through private pharmacies, hospitals, and clinics.
This move follows recommendations from the Drug Consultative Committee (DCC), which cited the risks of indiscriminate use and the subsequent increase in treatment failures and resistance to these vital medicines. The urgency of the proposal has been heightened by the recent expiration of patents for Bedaquiline and Delamanid, which opened the door for more pharmaceutical companies to manufacture and distribute these drugs, making them widely available in the open market.
Authorities warn that unregulated access to these potent drugs could undermine national TB control efforts by facilitating improper use, incomplete treatment regimens, and the emergence of strains resistant to the very medications designed to combat them. To enforce compliance, some states such as Puducherry have already launched raids on private chemists found violating the ban on private sales, reinforcing the policy that anti-TB drugs should be dispensed only through government channels to ensure strict adherence to treatment protocols and minimize the risk of resistance.
While the government aims to safeguard public health through these restrictions, patient advocacy groups and health experts have raised concerns about persistent shortages of anti-TB medicines in government clinics, warning that such gaps in supply could also lead to treatment interruptions and further fuel drug resistance. The shift away from private sales has already led pharmaceutical companies to focus on government tenders as the primary channel for distributing these drugs.
“The central government is considering a proposal to tighten the regulation of critical anti-tuberculosis (TB) drugs… following growing concerns of misuse and drug resistance,” reported News18.
As India strives to eliminate TB by 2025, authorities face the dual challenge of ensuring both responsible access to life-saving medications and a reliable supply for all patients in need.
Disclaimer:
This article is based on information from multiple news sources and government statements as of July 2025. The situation regarding anti-TB drug regulation and availability is evolving, and readers are advised to consult official health authorities or medical professionals for the latest updates and guidance on TB treatment.
